Tag: protein design
-
The commercial landscape of AI protein design — funding is at the $10^9 scale, but the number of approved de novo AI-designed protein drugs is zero
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All funding, valuation and milestone totals are attributed to each company’s press releases or media reports; many details cannot be independently verified and are marked as such. Vendor blog/preprint performance…
-
AI protein design’s validation reality — high in-silico scores, low wet-lab hit rates, and why an honest success-rate benchmark is still missing
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. This is the bottleneck layer of the AI-protein-design series, where its central question resolves. Self-reported in-silico success rates and improvement factors (from original authors and vendors) are separated throughout from…
-
Function — where AI protein design actually ships binding, catalysis and neutralization, and where it still fails. A ladder: binders on top, enzymes in the middle, antibodies at the bottom
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All success-rate, affinity and kcat/KM figures are attributed to the primary paper (Nature/Science) or company IR, with the media tier noted inline. Reported success rates are relative to the candidates…
-
The generative engine for protein design — backbone diffusion + inverse folding + a self-consistency filter that only checks folding, not function
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Every in-silico metric (scRMSD, pLDDT, sequence recovery, designability) is separated from wet-lab validation (X-ray/cryo-EM, binding, activity), and any vendor/lab claim is attributed. Benchmark or preprint SOTA is not read as…
-
The AI protein-design landscape — structure prediction is near-solved at the headline, but generative de novo design’s real bottleneck is the in-silico-metric-to-wet-lab-function gap
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All success-rate, hit-rate and efficiency figures are attributed to the reporting paper or company; some are company blogs or preprints rather than peer-reviewed data (noted inline). In-silico design metrics (pLDDT,…